Form 4: Hologic Director Nanaz Mohtashami Acquires RSUs

Hologic Inc. Director Nanaz Mohtashami acquired 3,190 restricted stock units, increasing her beneficial ownership to 7,371 units.

Summary

• Nanaz Mohtashami, a Director of Hologic Inc. (HOLX), acquired 3,190 restricted stock units (RSUs) on February 26, 2026.
• These RSUs are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders.
• The restricted stock units will be settled in shares of common stock on a one-for-one basis upon vesting.
• Following this transaction, Ms. Mohtashami beneficially owns a total of 7,371 restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a routine compensation event that increases a director's vested interest in the company's long-term success.

Positives

• Increased beneficial ownership by a director aligns management and shareholder interests.
• The acquisition of restricted stock units demonstrates a long-term commitment to the company's future performance.

Negatives

• No direct negatives are apparent from this routine insider transaction.

Risks

• The value of the restricted stock units is subject to the future performance of Hologic Inc.'s common stock.
• The RSUs do not vest until the 2027 Annual Meeting of Stockholders, meaning the director's full ownership is contingent on continued service and company performance until that date.

Future Outlook

The vesting schedule of the restricted stock units in 2027 implies a long-term incentive structure for the director, aligning their interests with the company's sustained performance over the next year.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to directors is a common practice in the healthcare technology industry, serving as a key component of executive and director compensation packages. This practice aims to align the interests of leadership with long-term shareholder value creation, a standard approach seen across peers like Intuitive Surgical (ISRG) and Stryker Corporation (SYK).

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of equity compensation for directors is a standard practice across publicly traded companies, including those in the medical technology sector.
• Companies such as Medtronic plc (MDT) and Abbott Laboratories (ABT) frequently grant RSUs to their non-employee directors, typically with vesting periods tied to continued service or specific performance milestones, similar to Hologic's approach.
• The amount of RSUs granted to directors varies widely based on company size, compensation philosophy, and individual director responsibilities, making a direct numerical comparison without more context difficult, but the mechanism itself is consistent with industry norms.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units by a director is a standard form of related party transaction (compensation) between the company and its board member.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director may be viewed positively as it aligns management interests with shareholder value creation.

Next Steps

• The restricted stock units are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation. While it shows continued alignment of director interests with the company's long-term performance, it does not present new information that would fundamentally alter the investment thesis for Hologic Inc. Therefore, a "hold" recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Hologic Inc., HOLX, Nanaz Mohtashami, Director, Restricted Stock Units, RSU, Insider Trading, Beneficial Ownership, Equity Compensation, Corporate Governance